Overview Dividends

(LH) Laboratory of America - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5049221055

Diagnostics,Laboratory,Testing,Services

LH EPS (Earnings per Share)

EPS Growth (3Y CAGR): -59.57%
EPS Trend (3Y Correlation): -46.7%

LH Revenue

Revenue Growth (3Y CAGR): 7.83%
Revenue Trend (3Y Correlation): 47.5%

Description: LH Laboratory of America October 14, 2025

Labcorp (NYSE: LH) operates two primary segments-Diagnostics Laboratories and Biopharma Laboratory Services-delivering a broad menu of clinical tests ranging from routine blood chemistry and urinalysis to high-complexity gene-based and esoteric assays, as well as specialty services in oncology, cardiovascular disease, pharmacogenetics, and occupational health.

The firm’s client base spans pharmaceutical and biotech firms, medical-device manufacturers, managed-care organizations, hospitals, government agencies, and individual consumers, with additional revenue streams from specimen-collection logistics, digital patient/provider portals, and companion-diagnostic development for drug pipelines.

Key performance indicators (KPIs) from Labcorp’s FY 2023 results show total revenue of approximately $13.9 billion, a 5 % year-over-year increase driven largely by growth in specialty testing and biopharma services; operating margin expanded to 11 % as the company leveraged automation and scale efficiencies. The segment’s outlook is closely tied to macro drivers such as an aging U.S. population, rising prevalence of chronic diseases, and the shift toward value-based reimbursement models that favor high-volume, high-margin molecular diagnostics.

For analysts seeking a deeper, data-driven view of Labcorp’s valuation dynamics, a quick look at ValueRay’s proprietary model can surface hidden sensitivities and scenario analyses that are not captured in standard consensus estimates.

LH Stock Overview

Market Cap in USD	23,226m
Sub-Industry	Health Care Services
IPO / Inception	1990-03-29

LH Stock Ratings

Growth Rating	61.7%
Fundamental	56.8%
Dividend Rating	47.3%
Return 12m vs S&P 500	-6.68%
Analyst Rating	4.45 of 5

LH Dividends

Dividend Yield 12m	1.42%
Yield on Cost 5y	2.11%
Annual Growth 5y	24.57%
Payout Consistency	17.4%
Payout Ratio	19.0%

LH Growth Ratios

Growth Correlation 3m	43.9%
Growth Correlation 12m	81.7%
Growth Correlation 5y	39.6%
CAGR 5y	10.51%
CAGR/Max DD 3y (Calmar Ratio)	0.61
CAGR/Mean DD 3y (Pain Ratio)	1.75
Sharpe Ratio 12m	0.86
Alpha	-4.19
Beta	0.871
Volatility	39.16%
Current Volume	1385.1k
Average Volume 20d	575.4k
Stop Loss	246.3 (-3%)
Signal	0.19

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (763.4m TTM) > 0 and > 6% of Revenue (6% = 809.0m TTM)

FCFTA 0.07 (>2.0%) and ΔFCFTA 1.89pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 10.16% (prev -3.95%; Δ 14.11pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.09 (>3.0%) and CFO 1.69b > Net Income 763.4m (YES >=105%, WARN >=100%)

Net Debt (5.90b) to EBITDA (1.87b) ratio: 3.15 <= 3.0 (WARN <= 3.5)

Current Ratio 1.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (84.1m) change vs 12m ago -0.24% (target <= -2.0% for YES)

Gross Margin 28.14% (prev 28.00%; Δ 0.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 77.56% (prev 74.72%; Δ 2.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.29 (EBITDA TTM 1.87b / Interest Expense TTM 226.9m) >= 6 (WARN >= 3)

Altman Z'' 3.43

(A) 0.08 = (Total Current Assets 4.09b - Total Current Liabilities 2.72b) / Total Assets 18.06b

(B) 0.47 = Retained Earnings (Balance) 8.50b / Total Assets 18.06b

(D) 0.89 = Book Value of Equity 8.47b / Total Liabilities 9.57b

Total Rating: 3.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 56.78

1. Piotroski 6.0pt = 1.0

2. FCF Yield 4.33% = 2.17

3. FCF Margin 9.36% = 2.34

4. Debt/Equity 0.77 = 2.21

5. Debt/Ebitda 3.15 = -1.97

6. ROIC - WACC (= -0.78)% = -0.97

7. RoE 9.25% = 0.77

8. Rev. Trend 47.51% = 3.56

9. EPS Trend -46.67% = -2.33

What is the price of LH shares?

As of November 03, 2025, the stock is trading at USD 253.96 with a total of 1,385,113 shares traded.
Over the past week, the price has changed by -7.87%, over one month by -9.12%, over three months by -3.50% and over the past year by +13.07%.

Is Laboratory of America a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Laboratory of America is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 56.78 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LH is around 246.78 USD . This means that LH is currently overvalued and has a potential downside of -2.83%.

Is LH a buy, sell or hold?

Laboratory of America has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy LH.

Strong Buy: 13
Buy: 3
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the LH price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	300	18.1%
Analysts Target Price	300	18.1%
ValueRay Target Price	272.3	7.2%

LH Fundamental Data Overview October 26, 2025

Market Cap USD = 23.23b (23.23b USD * 1.0 USD.USD)
P/E Trailing = 30.7808
P/E Forward = 15.7978
P/S = 1.7225
P/B = 2.7407
P/EG = 0.9454
Beta = 0.871
Revenue TTM = 13.48b USD
EBIT TTM = 1.20b USD
EBITDA TTM = 1.87b USD
Long Term Debt = 5.08b USD (from longTermDebt, last quarter)
Short Term Debt = 690.0m USD (from shortTermDebt, last quarter)
Debt = 6.55b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.90b USD (from netDebt column, last quarter)
Enterprise Value = 29.12b USD (23.23b + Debt 6.55b - CCE 647.3m)
Interest Coverage Ratio = 5.29 (Ebit TTM 1.20b / Interest Expense TTM 226.9m)
FCF Yield = 4.33% (FCF TTM 1.26b / Enterprise Value 29.12b)
FCF Margin = 9.36% (FCF TTM 1.26b / Revenue TTM 13.48b)
Net Margin = 5.66% (Net Income TTM 763.4m / Revenue TTM 13.48b)
Gross Margin = 28.14% ((Revenue TTM 13.48b - Cost of Revenue TTM 9.69b) / Revenue TTM)
Gross Margin QoQ = 29.66% (prev 28.34%)
Tobins Q-Ratio = 1.61 (Enterprise Value 29.12b / Total Assets 18.06b)
Interest Expense / Debt = 0.87% (Interest Expense 57.1m / Debt 6.55b)
Taxrate = 21.79% (66.4m / 304.7m)
NOPAT = 939.4m (EBIT 1.20b * (1 - 21.79%))
Current Ratio = 1.50 (Total Current Assets 4.09b / Total Current Liabilities 2.72b)
Debt / Equity = 0.77 (Debt 6.55b / totalStockholderEquity, last quarter 8.47b)
Debt / EBITDA = 3.15 (Net Debt 5.90b / EBITDA 1.87b)
Debt / FCF = 4.67 (Net Debt 5.90b / FCF TTM 1.26b)
Total Stockholder Equity = 8.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.23% (Net Income 763.4m / Total Assets 18.06b)
RoE = 9.25% (Net Income TTM 763.4m / Total Stockholder Equity 8.25b)
RoCE = 9.01% (EBIT 1.20b / Capital Employed (Equity 8.25b + L.T.Debt 5.08b))
RoIC = 6.57% (NOPAT 939.4m / Invested Capital 14.31b)
WACC = 7.34% (E(23.23b)/V(29.77b) * Re(9.22%) + D(6.55b)/V(29.77b) * Rd(0.87%) * (1-Tc(0.22)))
Discount Rate = 9.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.45%
[DCF Debug] Terminal Value 67.73% ; FCFE base≈1.10b ; Y1≈796.5m ; Y5≈444.7m
Fair Price DCF = 84.19 (DCF Value 7.00b / Shares Outstanding 83.1m; 5y FCF grow -32.37% → 3.0% )
EPS Correlation: -46.67 | EPS CAGR: -59.57% | SUE: -4.0 | # QB: 0
Revenue Correlation: 47.51 | Revenue CAGR: 7.83% | SUE: 0.65 | # QB: 0

Additional Sources for LH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle